Glenmark Life Sciences slips below issue price as stock falls 5%
Shares of (GLS) slipped below its issue price of Rs 720 per share on the BSE in intra-day trade on Monday as the stock declined 5 per cent to Rs 713.85. With today’s decline, the stock of the pharmaceutical company has slipped 11 per cent from its listing day high of Rs 799.95.
On Friday, August 6, 2021, GLS had made a quiet debut on the bourses as the shares listed at Rs 751.10, a 4 per cent premium against issue price on the BSE.
GLS, a developer and manufacturer of active pharmaceutical ingredients (APIs), is a wholly-owned subsidiary of Glenmark Pharmaceuticals. The company on Friday informed the stock exchanges that the board of directors of the company is scheduled to meet on Friday, August 13, 2021, to consider and approve the unaudited financial results of the company for the first quarter ended June 30, 2021 (Q1FY22).
GLS is a leading developer, manufacturer of select high value, non- commoditised APIs in chronic therapeutic areas, including CVS, CNS and pain management, diabetes and continues to branch into other APIs. It has a strong market share in select specialised APIs like Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology).
However, the company’s five largest customers accounted for more than 50 per cent of FY21 revenues with the promoter being the biggest customer. GLS does not typically have exclusivity arrangements with customers, including key customers. Reliance on a select group of customers may also constrain the company’s ability to negotiate arrangements, the brokerages said in IPO note.
The company’s top 10 products accounted for around two-third of FY21 revenue. If market growth in key products declines or if profit margins on products sold in key products decline, results of operations could be adversely affected. The business is subject to extensive government regulation and if they fail to obtain, maintain or renew their statutory and regulatory licenses, permits and approvals required to operate their business, results of operations and cash flows may be adversely affected, the brokerages said.
GLS’s API portfolio comprises specialised products, including niche and technically complex molecules, which reflects its ability to branch into other high value products. Although product concentration remains a key risk where top 10 products contribute 66.36 per cent. GLS aims to reduce this dependence, with planned capex in FY22, the brokerage firm GEPL Capital said in IPO note.
GLS’ FY21 P&L reflects benefits from Favipiravir (EBITDA margin 31 per cent). Interestingly, in the past 6 months (Jan-Jun’21), exports have largely been towards EM and sales have seen a declining trend. Also, Glenmark’s contribution has been negligible during this period.
Analysts at Dolat Capital expect revenue contribution from newly commercialised products to increase over the next five years. In addition, they see the complex API business as a key growth opportunity where GLS could leverage expertise in synthetic chemistry and analytical characterization to expand its existing technology platforms and complex API portfolio in oncology, peptides and iron compounds, thereby expanding existing portfolio of API products. Profit share clause in the CDMO segment could add profit optionality to this business, it added.
At 11:30 am, GLS was trading 3 per cent lower at Rs 724.95 on the BSE, as compared to a 0.30 per cent rise in the S&P BSE Sensex. A combined 2.73 million equity shares had changed hands on the counter on the NSE and BSE so far.
Glenmark Life Sciences Stock Makes a Tepid Debut Today. Check Share Price at BSE, NSE
Glenmark Life Science shares went up higher upon its debut on the stock markets. The price per share rose to Rs 756, a premium over the issue price of Rs 720 per equity share on the Bombay Stock Exchange (BSE). The stocks on the National Stock Exchange (NSE) debuted with a price of Rs 750 which was up by 4.17 per cent.
This IPO listing was a highly anticipated one due to the stellar performance it had on its subscription days from investors, the decent level of valuation of the company as well as the strong company financials. Upon listing the stock was expected to list at a premium of around 10 per cent to 15 per cent over its final issue price of Rs 720, at the higher end of the price band.
The Glenmark Life Sciences IPO had opened its Rs 1,514 crore initial public offering (IPO) earlier in July. The public issue was open for three days for subscription on the market as it opened on July 27 and closed on July 29. In that time the issue saw very robust participation from its investors. The issue consisted of a fresh issue of Rs 1,060 crore as well as an offer for sale (OFS) that aggregated up to Rs 453.60 crore with 6,300,000 equity shares with a Rs 2 face value. The Glenmark Life Sciences IPO was subscribed a total of 44.17 times. The price band for the issue was listed as Rs 695 to Rs 720 per equity share.
The non-institutional investors played the biggest part in that with a subscription of 122.54 times that of what they were allotted. The qualified institutional buyers were subscribed at around 36.97 times and the retail investors subscribed to the issue a total of 14.63 times against their allotted shares.
The company was incorporated in 2011 as a manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. Currently, Glenmark Life Sciences is active in many countries outside of India. These include the likes of Europe, North America, Latin America and Japan to name a few.
Speaking on the outlook of the company, ICICI Direct had said, “GLS has a good performance execution and clean regulatory track record. The company is also a leading developer and manufacturer of select high value, non-commoditised APIs in chronic therapies and works with 16 of the 20 largest generic companies globally. The growth momentum also has a strong undercurrent of global API industry growth.”
On the topic of the company’s financial performance and the growth it has seen, ICICI Direct added, “Revenues from regulated markets were 65.64% of FY21 revenues. As of FY21, GLS had a portfolio of 120 molecules globally, sold APIs in India and exported their APIs to multiple countries in Europe, US, Latin America, Japan and RoW. As of May 31, 2021, GLS had filed 403 drug master files (DMFs) and certificates of suitability to the monographs of the European Pharmacopoeia (CEPs). GLS work with 16 of the 20 largest generic companies globally.”
The company has distinctive strengths that lend to its growth. For one it is the leading manufacturer of specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management. It also has a strong foothold in the international market and ties to leading global generic companies. This combined with its strong financial track record in the past make it a strong investment choice.
Read all the Latest News, Breaking News and Coronavirus News here
Trade setup for Tuesday: Top 15 things to know before Opening Bell
The market wiped out gains in afternoon, but managed to claw back some gains in late trade and closed with moderate gains on August 9. However, the broader markets under-performed frontliners as the Nifty Midcap 100 index was down 0.73 percent and Smallcap 100 index declined 0.91 percent.
The BSE Sensex gained 125.13 points to close at 54,402.85, while the Nifty50 rose 20.10 points to 16,258.30 and formed bearish candle which resembles Doji kind of pattern on the daily charts as the closing was near its opening levels.
“The daily price action has formed a small bearish candle forming a lower High-low compared to the previous session, indicating short term breather. Since the past four trading sessions, the index continues to consolidate within 16,350-16,170 indicating rangebound action,” said Rajesh Palviya, VP - Technical and Derivative Research at Axis Securities.
He further said, “The next higher levels to be watched are around 16,350 levels. Any sustainable move above 16,350 levels may cause momentum towards 16,400-16,450 levels.”
“On the downside, any violation of an intraday support zone of 16,180 levels may cause profit booking towards 16,100-16,000 levels,” he added.
We have collated 15 data points to help you spot profitable trades:
Note: The open interest (OI) and volume data of stocks given in this story are the aggregates of three-month data and not of the current month only.
Key support and resistance levels on the Nifty
According to pivot charts, the key support levels for the Nifty are placed at 16,184.53, followed by 16,110.87. If the index moves up, the key resistance levels to watch out for are 16,326.33 and 16,394.47.
Nifty Bank
The Nifty Bank outperformed benchmark indices, rising 219.70 points to close at 36,028.95 on August 9. The important pivot level, which will act as crucial support for the index, is placed at 35,707.5, followed by 35,386.1. On the upside, key resistance levels are placed at 36,255.1 and 36,481.3 levels.
Call option data
Maximum Call open interest of 17.96 lakh contracts was seen at 16500 strike, which will act as a crucial resistance level in the August series.
This is followed by 16300 strike, which holds 15.43 lakh contracts, and 16000 strike, which has accumulated 14.76 lakh contracts.
Call writing was seen at 16300 strike, which added 1.8 lakh contracts, followed by 16200 strike, which added 1.04 lakh contracts and 16400 strike which added 83,350 contracts.
Call unwinding was seen at 16500 strike, which shed 2.71 lakh contracts, followed by 15900 strike which shed 1.93 lakh contracts, and 15800 strike which shed 1.42 lakh contracts.
Put option data
Maximum Put open interest of 32.85 lakh contracts was seen at 16000 strike, which will act as a crucial support level in the August series.
This is followed by 15500 strike, which holds 27.75 lakh contracts, and 15800 strike, which has accumulated 24.27 lakh contracts.
Put writing was seen at 16000 strike, which added 2.35 lakh contracts, followed by 16500 strike which added 1.91 lakh contracts, and 16100 strike which added 1.68 lakh contracts.
Put unwinding was seen at 15900 strike, which shed 85,800 contracts, followed by 15700 strike which shed 68,300 contracts, and 16,600 strike which shed 24,150 contracts.
Stocks with a high delivery percentage
A high delivery percentage suggests that investors are showing interest in these stocks.
28 stocks saw long build-up
An increase in open interest, along with an increase in price, mostly indicates a build-up of long positions. Based on the open interest future percentage, here are the top 10 stocks in which a long build-up was seen.
36 stocks saw long unwinding
A decline in open interest, along with a decrease in price, mostly indicates a long unwinding. Based on the open interest future percentage, here are the top 10 stocks in which long unwinding was seen.
74 stocks saw short build-up
An increase in open interest, along with a decrease in price, mostly indicates a build-up of short positions. Based on the open interest future percentage, here are the top 10 stocks in which a short build-up was seen.
27 stocks witnessed short-covering
A decrease in open interest, along with an increase in price, mostly indicates a short-covering. Based on the open interest future percentage, here are the top 10 stocks in which short-covering was seen.
Bulk deals
Glenmark Life Science: Polar Capital Funds Plc - Healthcare Opportunities Fund acquired 8.36 lakh equity shares in the company at Rs 732.55 per share on the NSE, the bulk deals data showed.
Mukand: Rajesh V Shah and his family members, Suketu V Shah and his family members, Isarnan Steel & Minerals, and Sidya Investments have collectively sold and transferred 2,34,25,628 equity shares of Mukand (or 16.57% of paid up equity), to Bajaj Sevashram, Bachhraj & Company, Bachhraj Factories and Sanrajnayan Investments in an inter-se transfer of shares between the promoter group entities of the company.
Rolex Rings: HSBC Pooled Investment Fund-HSBC Pooled Asian Equity Fund acquired 1,44,823 equity shares in the company at Rs 1,250 per shares on the NSE, the bulk deals data showed.
Quess Corp: Smallcap World Fund Inc bought 41,30,467 equity shares in the company at Rs 900 per share, whereas Ajit Isaac sold 20 lakh shares at Rs 900 per share and Fairbridge Capital (Mauritius) sold 30 lakh shares at Rs 899.99 per share on the BSE, the bulk deals data showed.
Zeal Aqua: TCG Funds Fund 1 bought 1.26 lakh equity shares in the company at Rs 158 per share on the BSE, the bulk deals data showed.
(For more bulk deals, click here)
Results on August 10, and Analysts/Investors Meeting
Results on August 10: Zomato, Coal India, Lupin, Power Grid Corporation of India, Aarti Surfactants, Ahluwalia Contracts (India), Aarey Drugs & Pharmaceuticals, Ashoka Buildcon, Balaji Telefilms, Mrs Bectors Food Specialities, Brookfield India Real Estate Trust REIT, Computer Age Management Services, Capacite Infraprojects, Century Plyboards, Chalet Hotels, Cochin Shipyard, Deepak Fertilisers, Eveready Industries, Galaxy Surfactants, Godrej Agrovet, Heranba Industries, Infibeam Avenues, IRB Infrastructure Developers, Jindal Steel & Power, Krishna Institute of Medical Sciences, Linde India, Manappuram Finance, Max Financial Services, Motherson Sumi Systems, Prestige Estates Projects, Pricol, Reliance Infrastructure, Sequent Scientific, Siemens, Spencers Retail, Trent, Tata Teleservices (Maharashtra), Whirlpool of India, and Wonderla Holidays will release quarterly earnings on August 10.
HeidelbergCement India: The company’s officials will meet representatives of Franklin Templeton and Global Alpha Capital Management on August 10.
Nippon Life India Asset Management: The company’s officials will meet analysts and investors on August 10, in a Emkay Confluence - Ideas for Tomorrow, and August 26 in DART India Virtual Conference Series 2021.
Ceat: The company’s officials will meet investors and analysts on August 10 & 11, in Emkay Annual Flagship Investor Conference 2021 - Ideas for Tomorrow, and August 24 in Edelweiss Auto Ancillary e-Conference.
Mahindra & Mahindra: The company’s officials will meet several funds and investors on August 11, in Emkay Virtual Investor Conference.
Nath Bio-Genes (India): The company’s officials will meet analysts and investors on August 11, to discuss Q1FY22 earnings.
Suryoday Small Finance Bank: The company’s officials will meet analysts and investors on August 12, to discuss the financial results.
Kirloskar Oil Engines: The company’s officials will meet analysts and investors on August 13, to discuss its Q1FY22 financial results.
Stocks in News
Bombay Dyeing: The company reported consolidated loss at Rs 107.9 crore in Q1FY22 against loss of Rs 129.1 crore in Q1FY21, revenue jumped to Rs 380.8 crore from Rs 91.2 crore YoY.
Shree Cement: The company reported sharply higher profit at Rs 661.7 crore in Q1FY22 against Rs 370.8 crore in Q1FY21, revenue jumped to Rs 3,449.5 crore from Rs 2,332.4 crore YoY.
Motilal Oswal Financial Services: ICRA upgraded the credit rating on long term debt instruments of Motilal Oswal Home Finance, a material subsidiary of the company to ‘AA-/Stable’ from ‘A+/Stable’.
Texmo Pipes and Products: The company has received orders from multiple contractors of HDPE Pipes worth Rs 121.59 crore to be executed within 6-7 months.
Timken India: The company reported higher profit at Rs 56.72 crore in Q1FY22 against Rs 3.15 crore in Q1FY21, revenue jumped to Rs 467.85 crore from Rs 160.23 crore YoY.
Tata Investment Corporation: The company reported higher consolidated profit at Rs 53.89 crore in Q1FY22 against Rs 18.40 crore in Q1FY21, revenue jumped to Rs 61.90 crore from Rs 30.90 crore YoY.
FII and DII data
Foreign institutional investors (FIIs) net bought shares worth Rs 211.91 crore, while domestic institutional investors (DIIs) net offloaded shares worth Rs 716.15 crore in the Indian equity market on August 9, as per provisional data available on the NSE.
Stocks under F&O ban on NSE
Six stocks - Canara Bank, Indiabulls Housing Finance, NALCO, RBL Bank, SAIL and Sun TV Network - are under the F&O ban for August 10. Securities in the ban period under the F&O segment include companies in which the security has crossed 95 percent of the market-wide position limit.